Effect of Apatinib Plus Pegylated Liposomal Doxorubicin vs Pegylated Liposomal Doxorubicin Alone on Platinum-Resistant Recurrent Ovarian Cancer
Sign Up to like & getrecommendations! Published in 2022 at "JAMA Oncology"
DOI: 10.1001/jamaoncol.2022.2253
Abstract: Key Points Question Does the addition of apatinib, a vascular endothelial growth factor receptor 2 tyrosine kinase inhibitor, to treatment with pegylated liposomal doxorubicin (PLD) improve progression-free survival in patients with platinum-resistant recurrent ovarian cancer?… read more here.
Keywords: pegylated liposomal; recurrent ovarian; platinum resistant; liposomal doxorubicin ... See more keywords
Advances in Ovarian Cancer Care and Unmet Treatment Needs for Patients With Platinum Resistance: A Narrative Review.
Sign Up to like & getrecommendations! Published in 2023 at "JAMA oncology"
DOI: 10.1001/jamaoncol.2023.0197
Abstract: Importance Platinum-based chemotherapy has been the standard of care for ovarian cancer for the past 3 decades. Although most patients respond to platinum-based treatment, emergence of platinum resistance in recurrent ovarian cancer is inevitable during… read more here.
Keywords: platinum resistant; ovarian cancer; treatment; resistant ovarian ... See more keywords
The Application of Biomaterials in the Treatment of Platinum‐Resistant Ovarian Cancer
Sign Up to like & getrecommendations! Published in 2019 at "ChemMedChem"
DOI: 10.1002/cmdc.201900450
Abstract: More than 70 % of women with ovarian cancer are diagnosed with advanced‐stage disease, which is initially treated with cytoreductive surgery, and combination chemotherapy with platinum‐based compounds. Most patients initially respond to platinum‐based therapy, but eventually… read more here.
Keywords: resistant ovarian; platinum; platinum based; ovarian cancer ... See more keywords
Optimizing treatment for platinum‐resistant ovarian clear cell carcinoma: Efficacy of gemcitabine and combination therapy with bevacizumab
Sign Up to like & getrecommendations! Published in 2025 at "Cancer"
DOI: 10.1002/cncr.70071
Abstract: Platinum‐resistant (PR) ovarian clear cell carcinoma (OCCC) is highly resistant to chemotherapy and has a poor prognosis. Both in‐vitro and clinical studies have suggested that gemcitabine (GEM) is particularly effective against OCCC. Moreover, a combination… read more here.
Keywords: platinum resistant; resistant ovarian; ovarian clear; cell carcinoma ... See more keywords
pH-Promoted Release of a Novel Anti-Tumour Peptide by “Stealth” Liposomes: Effect of Nanocarriers on the Drug Activity in Cis-Platinum Resistant Cancer Cells
Sign Up to like & getrecommendations! Published in 2018 at "Pharmaceutical Research"
DOI: 10.1007/s11095-018-2489-z
Abstract: PurposeTo evaluate the potential effects of PEGylated pH-sensitive liposomes on the intracellular activity of a new peptide recently characterized as a novel inhibitor of the human thymidylate synthase (hTS) over-expressed in many drug-resistant human cancer… read more here.
Keywords: peptide; drug; cis platinum; cancer ... See more keywords
Antibody–drug conjugates in ovarian cancer
Sign Up to like & getrecommendations! Published in 2024 at "memo - Magazine of European Medical Oncology"
DOI: 10.1007/s12254-024-00959-9
Abstract: Ovarian cancer (OC) management presents a challenging scenario in clinical practice due to its late diagnosis, high recurrence rate, and dismal 5‑year survival rate of 45%—especially in platinum-resistant cases. Antibody–drug conjugates (ADCs) are novel drugs… read more here.
Keywords: cancer; platinum resistant; ovarian cancer; antibody drug ... See more keywords
Pazopanib treatment of a platinum-resistant recurrence of a high-grade Sertoli cell tumor and assessment of the treatment response by FDG-PET/CT: A case report
Sign Up to like & getrecommendations! Published in 2018 at "Gynecologic Oncology Reports"
DOI: 10.1016/j.gore.2018.03.002
Abstract: Ovarian Sertoli cell tumors (SCTs) are rare sex cord tumors (Oliva et al., 2005). The standard treatment for high-grade SCTs is surgery followed by platinum-based chemotherapy. Although platinum-based chemotherapy is also an option for recurrent… read more here.
Keywords: platinum; high grade; sertoli cell; treatment ... See more keywords
Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035)
Sign Up to like & getrecommendations! Published in 2020 at "Gynecologic Oncology Reports"
DOI: 10.1016/j.gore.2020.100546
Abstract: Highlights • PI3K/AKT pathway alterations are frequently seen in ovarian cancer, providing rationale for targeted AKT inhibition.• AKT inhibitor MK-2206 in platinum resistant high grade serous ovarian cancer was notable for dermatologic toxicity.• Best response… read more here.
Keywords: grade serous; high grade; inhibitor 2206; resistant high ... See more keywords
New approaches for targeting platinum-resistant ovarian cancer.
Sign Up to like & getrecommendations! Published in 2020 at "Seminars in cancer biology"
DOI: 10.1016/j.semcancer.2020.08.013
Abstract: Platinum is the backbone of systemic treatment in ovarian cancer and development of platinum resistance is associated with poor survival. Here, we perform a comprehensive review of the literature regarding resistance mechanisms and advances in… read more here.
Keywords: platinum; resistant ovarian; resistance; ovarian cancer ... See more keywords
Adding bevacizumab to single agent chemotherapy for the treatment of platinum-resistant recurrent ovarian cancer: A cost effectiveness analysis of the AURELIA trial.
Sign Up to like & getrecommendations! Published in 2017 at "Gynecologic oncology"
DOI: 10.1016/j.ygyno.2017.02.039
Abstract: OBJECTIVE AURELIA, a randomized phase III trial of adding bevacizumab (B) to single agent chemotherapy (CT) for the treatment of platinum-resistant recurrent ovarian cancer, demonstrated improved progression free survival (PFS) in the B+CT arm compared… read more here.
Keywords: platinum resistant; single agent; treatment platinum; cost ... See more keywords
Cost-effectiveness of niraparib, rucaparib, and olaparib for treatment of platinum-resistant, recurrent ovarian carcinoma.
Sign Up to like & getrecommendations! Published in 2020 at "Gynecologic oncology"
DOI: 10.1016/j.ygyno.2020.02.030
Abstract: BACKGROUND Olaparib was approved on December 19, 2014 by the US FDA as 4th-line therapy (and beyond) for patients with germline BRCA1/2 mutations; rucaparib was approved on December 19, 2016 as 3rd-line therapy (and beyond)… read more here.
Keywords: platinum; cost; pfs month; platinum resistant ... See more keywords